Stock Price & Analysis

Based on the technical and fundamental analysis of BMRN's current market position, the stock appears to be in a bearish trend with the current price at $63.51, showing weakness in both pre-market and regular trading sessions. The RSI at 47.43 indicates neutral momentum but slightly leaning towards oversold territory.

The stock has strong institutional backing with recent analyst coverage showing optimistic targets - JPMorgan set a $109 price target, while Wolfe Research initiated coverage with a $95 target. However, the stock is currently trading below both its 20-day moving average ($63.03) and 60-day moving average ($64.79), suggesting near-term technical weakness.

The company's fundamentals remain solid with strong VOXZOGO performance, having over 3,800 patients under treatment by Q3 2024. Management has reiterated achieving ~$4 billion in total revenue by 2027 with 40% adjusted operating margins starting in 2026.

Given the current technical weakness but strong fundamental outlook and analyst confidence, holding current positions or accumulating on further dips below the Fibonacci support level of $62.08 would be more prudent than selling at current levels.

Based on the provided data and technical analysis, BMRN stock is projected to reach $92 by the end of 2025, representing a 45% upside from current price of $63.51. This forecast is driven by strong growth in VOXZOGO sales and expanding operating margins.

JPMorgan has reiterated an "Overweight" rating with a $109 price target, citing BioMarin's goal of achieving ~$4 billion in total revenue by 2027 and low-to-mid 40% adjusted operating margin starting with 40% in 2026.

The company's VOXZOGO treatment for achondroplasia continues showing robust global demand with over 3,800 patients receiving treatment. Supply constraints have been resolved, indicating healthy potential for continued strong growth and label expansion.

The S1 support level for BMRN Stock is $62.08 ,The R1 resistant level for BMRN Stock is $64.68.

As of the end of day on 2025-02-11, the price of BMRN Stock was $64.49.

The target price for BMRN Stock according to analyst rating is 101.25, with the highest price target at 127.00 and the lowest at 70.00. Analysts have a Strong Buy rating on BMRN Stock overall.

The market cap of BMRN is $12.1B.

Based on the provided data, I'll analyze if BMRN is overvalued through multiple aspects:

Valuation Metrics BMRN's key valuation metrics have shown significant improvement in 2024:

• P/E ratio decreased from 81.83 (Q1) to 42.13 (Q3)
• EV/EBITDA reduced from 58.94 to 26.14
• P/S ratio declined from 6.84 to 5.01

Financial Performance The company demonstrated strong execution in Q3 2024:

• Revenue reached $745.74M, up 28% YoY
• Adjusted EPS of $0.91, nearly double from $0.46 YoY
• VOXZOGO sales grew 54% to $190M

Growth Outlook Management has reaffirmed positive long-term targets:

• Revenue target of $4B by 2027
• 40% adjusted operating margin starting 2026
• Strong VOXZOGO global demand with over 3,800 patients

Analyst Sentiment Recent analyst actions show mixed but generally positive views:

• JPMorgan: $109 PT, Overweight rating
• UBS: $106 PT, Buy rating
• Baird: $65 PT, Hold rating
• Average PT of $96.03 implies ~51% upside

Technical Analysis The stock is showing signs of oversold conditions:

• RSI reading of 29.4 indicates oversold territory
• Trading below both 20-day ($63.03) and 60-day ($64.79) moving averages
• Current price shows technical weakness but potential for reversal

Conclusion: BMRN is not overvalued at current levels. While facing near-term technical weakness, the company's improving valuation metrics, strong financial performance, and positive long-term outlook suggest the stock offers value at current prices. The average analyst price target of $96.03 and oversold technical conditions further support this conclusion.

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Based on the provided data and market analysis, here is the 2030 price prediction for BMRN stock:

BioMarin Pharmaceutical (BMRN) stock is projected to reach $115-120 by 2030, driven by the company's strong pipeline expansion and projected revenue growth to $4 billion by 2027. The company's standout performer VOXZOGO for achondroplasia treatment and expanding global market presence support this bullish outlook. The recent analyst consensus and strong interest coverage ratio indicate solid financial fundamentals that could sustain long-term growth [1,5].

BMRN has a total of 3401 employees.